Product Information
TRI-VYLIBRA LO TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1049 per EA under NDC 50102023113. Its NADAC has been published 373 times since May 8, 2019.
Manufacturer
Afaxys Pharma, LLCNDC
50102023113
Classification
Generic
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205762On Market Since
11/4/2016
Price Statistics
The NADAC for TRI-VYLIBRA LO TABLET has been published 373 times since May 8, 2019, and over the history we have for it it has declined 50.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1049 per EA |
|---|---|
| All-time high | $0.2607 (Jun 12, 2019) |
| All-time low | $0.0903 (Nov 20, 2024) |
| 52-week high | $0.1162 |
| 52-week low | $0.1049 |
| Median price | $0.1611 |
| Average price | $0.1584 |
| Largest weekly change | -27.8% (Apr 17, 2024) |
| Weeks tracked | 373 |
| Tracking since | May 8, 2019 |
Generic Alternatives
The matcher finds 7 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 7 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRI-VYLIBRA LO TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-VYLIBRA LO TABLET, manufactured by Afaxys Pharma, LLC, is $0.1049 per EA (NDC 50102023113), effective Jun 24, 2026.
How has the price of TRI-VYLIBRA LO TABLET changed over time?
Over the history we have for it, the NADAC for TRI-VYLIBRA LO TABLET has declined 50.3%. It has been tracked across 373 weekly CMS publications since May 8, 2019.
What are the highest and lowest recorded NADAC prices for TRI-VYLIBRA LO TABLET?
Since May 8, 2019, the NADAC for TRI-VYLIBRA LO TABLET has ranged from a low of $0.0903 (Nov 20, 2024) to a high of $0.2607 (Jun 12, 2019), with a median of $0.1611 per EA.
Are there cheaper alternatives to TRI-VYLIBRA LO TABLET?
7 NADAC-published products share the same active ingredient, strength, and dosage form as TRI-VYLIBRA LO TABLET, but none are currently priced below it.
Who manufactures TRI-VYLIBRA LO TABLET?
TRI-VYLIBRA LO TABLET (NDC 50102023113) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification